Adeno-Associated Virus Delivery Limitations for Neurological Indications
dc.contributor.author | Benatti, Hector Ribeiro | |
dc.contributor.author | Gray-Edwards, Heather L | |
dc.date.accessioned | 2023-01-24T13:41:00Z | |
dc.date.available | 2023-01-24T13:41:00Z | |
dc.date.issued | 2022-01-17 | |
dc.identifier.citation | Benatti HR, Gray-Edwards HL. Adeno-Associated Virus Delivery Limitations for Neurological Indications. Hum Gene Ther. 2022 Jan;33(1-2):1-7. doi: 10.1089/hum.2022.29196.hrb. PMID: 35049369. | en_US |
dc.identifier.eissn | 1557-7422 | |
dc.identifier.doi | 10.1089/hum.2022.29196.hrb | en_US |
dc.identifier.pmid | 35049369 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/51576 | |
dc.description.abstract | In this commentary we discuss pitfalls and limitations of current adeno-associated virus (AAV) delivery routes, dose scaling, and the extrapolation of animal data to first-in-human (FIH) AAV clinical trials. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Human Gene Therapy | en_US |
dc.relation.url | https://doi.org/10.1089/hum.2022.29196.hrb | en_US |
dc.title | Adeno-Associated Virus Delivery Limitations for Neurological Indications | en_US |
dc.type | Editorial | en_US |
dc.source.journaltitle | Human gene therapy | |
dc.source.volume | 33 | |
dc.source.issue | 1-2 | |
dc.source.beginpage | 1 | |
dc.source.endpage | 7 | |
dc.source.country | United States | |
dc.identifier.journal | Human gene therapy | |
dc.contributor.department | Horae Gene Therapy Center | en_US |
dc.contributor.department | Radiology | en_US |
This item appears in the following Collection(s)
-
Radiology Publications [1231]